84 related articles for article (PubMed ID: 27225053)
1. [Oncological results in high grade prostate cancer treated surgically].
Aguilera A; Alonso-Dorrego JM; Bañuelos B; Cisneros J; González P; Díez J
Arch Esp Urol; 2016 May; 69(4):162-71. PubMed ID: 27225053
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
[TBL] [Abstract][Full Text] [Related]
4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
5. Post-radical prostatectomy predictive factors for biochemical recurrence.
Molina Escudero R; Herranz Amo F; Páez Borda A; Hernández Fernández C
Arch Esp Urol; 2013 Oct; 66(8):807-14. PubMed ID: 24136484
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
7. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
8. Long-term oncological outcomes after laparoscopic radical prostatectomy.
Hruza M; Bermejo JL; Flinspach B; Schulze M; Teber D; Rumpelt HJ; Rassweiler JJ
BJU Int; 2013 Feb; 111(2):271-80. PubMed ID: 22757970
[TBL] [Abstract][Full Text] [Related]
9. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
[TBL] [Abstract][Full Text] [Related]
10. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
11. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.
O'Neil LM; Walsh S; Cohen RJ; Lee S
BJU Int; 2015 Oct; 116 Suppl 3():42-8. PubMed ID: 26218868
[TBL] [Abstract][Full Text] [Related]
12. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
[TBL] [Abstract][Full Text] [Related]
13. First Danish single-institution experience with radical prostatectomy: impact of surgical margins on biochemical outcome.
Vrang ML; Røder MA; Vainer B; Christensen IJ; Gruschy L; Brasso K; Iversen P
Scand J Urol Nephrol; 2012 Jun; 46(3):172-9. PubMed ID: 22320899
[TBL] [Abstract][Full Text] [Related]
14. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
15. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
16. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
17. Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases.
Kates M; Sopko NA; Han M; Partin AW; Epstein JI
J Urol; 2016 Feb; 195(2):337-42. PubMed ID: 26264998
[TBL] [Abstract][Full Text] [Related]
18. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up.
Rouanne M; Rode J; Campeggi A; Allory Y; Vordos D; Hoznek A; Abbou CC; De La Taille A; Salomon L
Scand J Urol; 2014 Apr; 48(2):131-7. PubMed ID: 23883410
[TBL] [Abstract][Full Text] [Related]
19. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience.
Audenet F; Comperat E; Seringe E; Drouin SJ; Richard F; Cussenot O; Bitker MO; Rouprêt M
Urol Oncol; 2011; 29(6):602-7. PubMed ID: 19926312
[TBL] [Abstract][Full Text] [Related]
20. Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.
Servoll E; Saeter T; Vlatkovic L; Lund T; Nesland J; Waaler G; Axcrona K; Beisland HO
BJU Int; 2012 May; 109(10):1489-94. PubMed ID: 21933333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
